... the end in inflammation
Founders and Scientific Advisory Board
The Founders and members of the Scientific Advisory Board are among the most distinguished scientists in their respective fields. They include:
- Steven B. Abramson, MD - Vice Dean for Education, Faculty and Academic Affairs; Professor of Medicine and Pathology at New York University Medical Center
- David Armistead, PhD - Former Vice President and Site head for the Amgen Cambridge Research Center
- Francis J. Bullock, PhD - Former Senior Vice President Research, Schering-Plough Research Institute
- Per Gjorstrup, MD PhD - Chief Medical Officer
- Robert Kamen, PhD - Former President, Abbott Bioresearch Center
- George Milne, PhD - Venture Partner, Radius Ventures
- Michael Morrissey, PhD - Executive Vice President, Exelixis
- K.C. Nicolau, PhD - Chairman, Department of Chemistry, Scripps Research Institute
- Nicos A. Petasis, PhD - Harold E & Lillian M Moulton Chair and Professor of Chemistry, University of Southern California
- Bengt Samuelsson, MD, D.Med.Sc. - Nobel Prize Laureate, 1982 in Medicine; Former President, Karolinska Institute, Stockholm, Sweden
- Charles Serhan, PhD - Simon Gilman Professor of Anaestesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and Director of the Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital
- Thomas Van Dyke, PhD - Professor; Director, Clinical Research Center, Boston University Goldman School of Dental Medicine; Director of Post-Graduate Periodontology
The Resolvin "many-to-one" approach will, for the first time, address the immune system redundancy as a major obstacle to identifying highly efficacious therapies for chronic inflammatory diseases.